

## State of Oklahoma SoonerCare



## Tecartus® (Brexucabtagene Autoleucel) Prior Authorization Form

Member Name:	Date of Birth:		Member ID#:
Drug Information			
☐ Physician billing (HCPCS code:	:) S	tart Date:	
Billing Provider Information			
SoonerCare Provider ID:	Provider Name:		
Provider Phone:	Provider Fax:		
Prescriber Information			
Prescriber NPI:	Prescriber Name	e:	
Prescriber Phone:	_ Prescriber Fax:		Specialty:
<b>Criteria</b>			
For Authorization:  1. Please include the most recent office visit note or clinical summary from the hospital to support your request. Is this information attached? Yes No  2. Is the health care facility on the certified list to administer CAR T-cells? Yes No  3. Is the health care facility trained in the management of cytokine release syndrome (CRS) and neurologic toxicities? Yes No  4. Will the health care facility comply with the Tecartus® Risk Evaluation and Mitigation Strategy (REMS) Program requirements? Yes No  5. Please indicate the diagnosis and information:    Mantle cell lymphoma			

**knowledge.**Failure to complete this form in full and attach requested clinical notes will result in processing delays.

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.

All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

**Prescriber Signature:** 

## **CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 176 7/28/2022